Insider Transactions in Q4 2022 at Athira Pharma, Inc. (ATHA)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 28
2022
|
Glenna Mileson Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+23.82%
|
$100,000
$2.85 P/Share
|
|
Dec 02
2022
|
Kelly A Romano |
BUY
Open market or private purchase
|
Direct |
30,000
+43.91%
|
$90,000
$3.29 P/Share
|
|
Nov 18
2022
|
Mark James Litton President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
662
+0.51%
|
$1,324
$2.74 P/Share
|
|
Nov 18
2022
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
657
+1.05%
|
$1,314
$2.74 P/Share
|
|
Nov 18
2022
|
Glenna Mileson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
763
+0.69%
|
$1,526
$2.74 P/Share
|
|
Nov 15
2022
|
Hans Moebius Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+7.06%
|
$15,000
$3.29 P/Share
|
|
Oct 28
2022
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,700
+5.68%
|
$3,700
$1.35 P/Share
|
|
Oct 13
2022
|
Hans Moebius Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,881
+11.47%
|
$7,881
$1.35 P/Share
|